21<sup>st</sup> CARDIOVASCULAR SUMMIT **TCTAP 2016** April 26-29, 2016

COeX, Seoul, Korea

## CAS Should Replace CEA in Patients Eligible

# for Bypass Surgery with Multilevel

# Atherosclerosis

Prof.. Piotr Pieniazek MD, PhD



John Paul II Hospital in Krakow, Jagiellonian University Institute of Cardiology, Krakow, Poland



### Multilevel atherosclerosis – unfavourable prognosis Patient with severe carotid artery stenosis coexisting with multivessel coronary disease

Is a patient with **multilevel atherosclerosis** (simultaneous presence of clinically relevant atherosclerotic lesions in at least two major vascular territories)

### that means

# unfavourable long term prognosis

REACH registry: 3-year observation: myocardial infarction/stroke/vascular death/rehospitalization was 40.5% for patients symptomatic in multiple vascular sites vs. 25.5% for patients with symptomatic vascular disease in one vascular site (P,0.001)

Tendera M et al. EuHeartJ 2011, Alberts MJ et al. EuHeartJ 2009

# Severe carotid disease in patients referred for cardiac surgery patients accepted for CAS:

54 – 77% patients with significant ICA stenosis has coexisting coronary artery disease,
1,2 – 7% of those has multivessel coronary artery disease and is referred for CABG,
the others (12 - 41%) are referred for PCI

In patients accepted for CABG:

- significant ICA stenosis ≥ 80% is found in 6-12% of patients
- ICA stenosis of  $\geq$  50% is found in 15-22% of patients

about 40% of patients with left main coronary artery stenosis have ICA stenosis of ≥
 50%

#### In patients referred for AVR:

• 18% have ICA stenosis >50%

Cremonesi A et al. EuroIntervention 2009; Pieniazek P et al. JEVT 2008; Hofman R et al. Heart 2005, Naylor AR J Cardiovasc Surg 2009

#### Diagnostic evaluation of carotid arteries in patients requiring cardiac surgery



European Heart Journal (2011) **32**, 2851–2906 doi:10.1093/eurheartj/ehr211 ESC GUIDELINES

# ESC Guidelines on the diagnosis and treatment of peripheral artery diseases

Recommendations	Class <sup>a</sup>	Levelb
In patients undergoing CABG, DUS scanning is recommended in patients with a history of cerebrovascular disease, carotid bruit, age ≥70 years, multivessel CAD, or LEAD.	Ì	B

#### ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline


2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/ SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease

#### **Class IIa**

1. Carotid duplex ultrasound screening is reasonable before elective CABG surgery in patients older than 65 years of age and in those with left main coronary stenosis, PAD, a history of cigarette smoking, a history of stroke or TIA, or carotid bruit. *(Level of Evidence: C)* 

#### The practice in our center:

To perform carotid doppler in almost every patient accepted for cardiac surgery



#### Diagnostic evaluation of carotid arteries in patients requiring cardiac surgery

#### Other imaging studies:



European Heart Journal doi:10.1093/eurheartj/ehu278 ESC/EACTS GUIDELINES


# 2014 ESC/EACTS Guidelines on myocardial revascularization

MRI, CT, or digital subtraction angiography may be considered if carotid artery stenosis by ultrasound is >70% and myocardial revascularization is contemplated.

ПЬ С


#### Carotid screening not recommended:

Screening for carotid stenosis is not indicated in patients with unstable CAD requiring emergent CABG with no recent stroke/TIA.





#### The etiology of stroke associated with cardiac surgery




 stroke is the most severe complication of CABG: about 22% of patients who had a perioperative stroke die, many remain permamently disabled

- about 60% of strokes associated with cardiac surgery are embolic
- (embolic material mostly from ascending aorta during clamping, but also may origin
- from the unstable carotid plaque)

Likosky DS. Stroke 2003

#### The risk of stroke associated with cardiac surgery

#### Neurologically asymptomatic ICA stenosis



Other important factors:

- ascending aorta atherosclerosis
- postoperative atrial fibrillation


#### The decision on the revascularization strategy



European Heart Journal (2011) **32**, 2851–2906 doi:10.1093/eurheartj/ehr211 ESC GUIDELINES

#### ESC Guidelines on the diagnosis and treatment of peripheral artery diseases

The indication for carotid revascularization should be individualized after discussion by a multidisciplinary team including a neurologist.



In case of patients with severe, multilevel atherosclerosis in our center multidisciplinary team consists of:

- Invasive cardiologist
- Cardiologist (non-invasive)
  - Cardiac surgeon
  - Vascular surgeon
    - Neurologist
    - Anesthetist

#### **Currently available revascularization strategies**

If carotid revascularization is indicated, the timing of the carotid and coronary interventions should <u>be decid</u>ed according to the clinical presentation, level of emergency, and severity of carotid disease and CAD.

#### **Conventional - surgical**

#### Novel, hybrid

Simultaneous CEA+CABG

Staged CEA-CABG

**Reverse - staged CABG-CEA** 

Simultaneous, hybrid CAS+CABG

Staged CAS-CABG

Staged CAS + PCI

### The guidelines



European Heart Journal (2011) **32**, 2851–2906 doi:10.1093/eurheartj/ehr211 ESC GUIDELINES

# ESC Guidelines on the diagnosis and treatment of peripheral artery diseases

Recommendations

Class<sup>a</sup> Level<sup>b</sup>

С

6

С

llb

Ш

In patients undergoing CABG, with a <6-month history of TIA/stroke and corresponding carotid artery disease

Carotid revascularization is recommended in 70–99% carotid stenosis.

Carotid revascularization may be considered in 50–69% carotid stenosis, depending on patient-specific factors and clinical presentation.

Carotid revascularization is not recommended if the carotid stenosis is <50%.

#### ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline

2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/ SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease

#### Class IIa

Carotid revascularization by CEA or CAS with embolic protection before or concurrent with myocardial revascularization surgery is reasonable in patients with greater than 80% carotid stenosis who have experienced ipsilateral retinal or hemispheric cerebral ischemic symptoms within 6 months. *(Level of Evidence: C)* 

Stroke 2011

#### The guidelines – the approach to the asymptomatic ICA stenosis before CABG



European Heart Journal (2011) **32**, 2851–2906 doi:10.1093/eurheartj/ehr211 ESC GUIDELINES

6

C

llb

lb

# ESC Guidelines on the diagnosis and treatment of peripheral artery diseases

In patients undergoing CABG with no history of TIA/ stroke within 6 months

Carotid revascularization may be considered in men with bilateral 70–99% carotid stenosis or 70–99% carotid stenosis and a contralateral occlusion.

Carotid revascularization may be considered in men with 70–99% carotid stenosis and ipsilateral previous silent cerebral infarction.

#### ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline

2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/ SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease

#### **Class IIb**

In patients with asymptomatic carotid stenosis, even if severe, the safety and efficacy of carotid revascularization before or concurrent with myocardial revascularization are not well established. (Level of Evidence: C)

Stroke 2011

## **Revascularization options**

	Operative mortality	Death $\pm$ Ipsilat CVA	Death $\pm$ any CVA	DEATH $\pmany\text{CVA}\pm\text{MI}$
(1) Synchronous				
CEA + CABG				
CEA pre-bypass				
Observed risk	245/5386	307/4189	442/5386	395/3426
Risk% (95%CI)	4.5% (3.9-5.2)	7.3% (6.4-8.2)	8.2% (7.1-9.3)	11.5% (10.1-13.1)
Heterogeneity (p=)	0.1469	0.0423	0.0000	0.0000
CEA performed on bypass				
Observed risk	40/844	52/807	68/844	26/273
Risk%	4.7% (3.1-6.4)	6.4% (4.7-8.2)	8.1% (5.8-10.3)	9.5% (5.9-13.1)
Heterogeneity (p=)	0.1802	0.3732	0.0770	0.3399
(2) Synchronous CEA+ off-pump CABG				
Observed risk	5/324	5/318	7/318	11/309
Pooled risk (%)	1.5% (0.3-2.8)	1.6% (0.4-2.8)	2.2% (0.7-3.7)	3.6% (1.6-5.5)
Heterogeneity (p=)	1.00	1.00	1.00	0.99
(3) Staged CEA-CABG				
Observed risk	36/917	39/809	56/917	72/709
Risk%	3.9% (1.1-6.7)	4.8% (2.8-6.8)	6.1% (2.9-9.3)	10.2% (7.4-13.1)
Heterogeneity (p=)	<0.0001	<0.0001	<0.0001	<0.0001
(4) Reverse-staged CABG-CEA				
Observed risk	6/302	3/87	22/302	11/221
Risk%	2.0% (0.0-6.1)	3.4% (0.0-9.8)	7.3% (1.7-12.9)	5.0% (0.0-10.6)
Heterogeneity	<0.0001	0.0060	<0.0001	0.0102
(5) Staged CAS + CABG				
Observed risk	42/760	47/627	69/760	61/649
Risk%	5.5% (3.4-7.6)	7.5% (4.5-10.5)	9.1% (6.2-12.0)	9.4% (7.0-11.8)
Heterogeneity	0.50	0.16	0.12	0.33

#### Naylor AR Eur J Vasc Endovasc Surg (2009)

### Hybrid CAS+CABG - Krakow data


Mo.Ma NPD

Start at: 7:20 RICA CAS




**Blood aspiration** 

Transfer to the operating room



**Result: RICA CAS** 

×



LIMA-LAD, SvG-Mg, -Dg, -RPD



At 8:30 the cardiac surgery starts

Cannulation

### Hybrid CAS + cardiac surgery – the data

	n (pts)	Study years	Ipsilateral stroke	Any stroke	MI	death	total
SHARP study	101	2006 - 2007	0	2 (2%)	0	2 (2%)	4 (4%)
Velissaris et al.	90	2003 - 2010	0	1 (1.1%)	0	1 (1.1%)	2 (2.2%)
Guerra et al.	23	2007 - 2008	0	0	0	1 (4.3%)	1 (4.3%)
Palombo et al.	22	2005 - 2008	0	1 (4.5%)	0	0	1 (4.5%)
Chiarello et al.	132	2004 - 2014	1 (0.75%)	0	0	5 (3.8%)	0 (4.5%)

Versaci F et al. JACC Cardiovasc Interv, 2009; , Velissaris et al. J Vasc, Surg 2011, Guerra et al. Interact Cardiovasc Thorac Surg 2009 Palombo et al. J Cardiovasc Surg, 2009, Chiarello L Ann Thorac Surg 2015;

#### **Hybrid CAS+CABG –** Our Experience !!!!

	n=51
age (years)	69,9 ± 6.5, range 53 – 83
male	38 (74%)
Ipsilateral stroke/TIA	16 (31%)
CCS class IV/UA	15 (29%)
NSTEMI	7 (14%)
Left main stenosis	16 (31%)
Mean carotid stenosis rate	85.5±10%, range 60-99%
Proximal NPD device	24 (47%)
Closed-cell/mesh-covered stent	48 (94%)
euroSCORE II	2.8 ± 1.3%, range 1.15 -6.91%
Isolated CABG	46 (90%)
Other cardiac surgery*	5 (10%)
Drainage (ml)	798.6 ±390, range 160-1800

\*isolated AVR, AVR+CABG, left ventricle aneurysmectomy and CABG

#### Hybrid CAS+CABG – our experience (in-hospital & 30-day outcome)

n=51	In-hospital	30-day
Death	2 (3.9%)	0
Myocardial infarction	1 (1.9%)	0
Stroke	0	0
	3 (5.9%)	


One cardiac surgery associated death as a result of multiorgan failure in a patient after CAS+ CABG and left ventricle aneurysmectomy;

Another cardiac surgery associated death in a patient, who underwent CAS+ isolated AVR cause by a failure to wean off extracorporeal circulation

Myocardial infarction on a 2<sup>nd</sup> postoperative day in a patient who had CAS+ isolated CABG treated by successful RCA PCI.

### **Staged CAS - CABG**

**Day 1**: Patient with a history of right hemispheric stroke and stable CCS class II angina



#### **Staged CAS-CABG**

According do Naylor's metaanalysis (11 studies, 760 procedures) CAS-CABG has similar outcome to CEA-CABG:

#### -Death/any cerebrovascular accident/MI of 9.4%, but

- -Almost half (n=356) of patients come from one trial by van der Heyden et al.
- -The vast majority (87%) of patients was neurologically asymptomatic

### -Neuroprotection devices were not routinely used

- CAS-CABG registries by van der Heyden et al.
- -*Circulation 2007*: CAS-CABG performed in 356 neurologically asymptomatic patients: death/stroke/MI - 6.7%
- JACC Cardiovasc Interv 2011: CAS-CABG performed in 57 with prior neurological symptoms: death/stroke/MI 12.3%

#### **Staged CAS-CABG – Our Experience**

	n=40
age (years)	67.6 ± 6.8, range 55-84
male	
Ipsilateral stroke/TIA	21 (52.5%)
CCS class II	
Left main stenosis	12 (30%)
Mean carotid stenosis rate	85.6± 8%, range 60-99%
Proximal NPD device	20 (50%)
Closed-cell/mesh-covered stent	35 (87.5%)
euroSCORE II	1.9 ± 1 %, range 0.85-4.95%
Isolated CABG	35 (87.5%)
Other cardiac surgery*	5 (12.5%)
Drainage (ml)	733± 307, range 300-1500

Bental de Bono+CABG, AVR+CABG, mitral valve repair +CABG

### **Staged CAS-CABG – Our Experience**

n=40	In-hospital	30-day
Death	1 (2.5%)	0
Myocardial infarction		0
Stroke	0	0
	1 (2.5%)	

-one death on the 3<sup>rd</sup> postoperative day due to cardiogenic shock in a patient who underwent CAS+AVR+CABG

### **Antiplatelet/antithrombotic treatment strategy**

	Hybrid CAS+CABG	Staged CAS-CABG
1.	Before procedure: ASA 75 - 100mg/day	1.Before CAS procedure: ASA 75 - 100mg/d
	chronically or started at least 3 days before	chronically or started at least 3 days before and
	procedure.	clopidogrel loading dose of 300 mg or 75 mg
2.	During CAS: UFH (100mg/kg) to maintain	1x1 for at least 4 days
	ACT > 250 ms.	2. During CAS: UFH (100mg/kg) to maintain
3.	During CABG: UFH (100mg/kg) to maintain	ACT > 250 ms.
	ACT > 250 ms.	3. Patient accepted for CABG
4.	In the end of CABG: protamin (titrated.	4.Clopidogrel for at least a month
	After CABG: Clopidogrel (loading dose	5.Clopidogrel withdrawn 5-7 days before CABG
5.	<b>300mg</b> ) started at least at 6 <sup>th</sup> postoperative	6. CABG
	hour (after extubation) depending on	7.Clopidogrel could be re-administered in the
	drainage, then continued <b>75 mg/day</b> for 3	perioperative period and continued up to 3
	months.	months.

#### CAS or CEA prior to cardiac surgery???

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
CEA or CAS should be performed by teams achieving a combined death/stroke rate at 30 days of: <3% in patients without previous neurological symptoms <6% in patients with previous neurological symptoms.	Ĩ	A
It is recommended to individualize the indication for carotid revascularization after discussion by a multidisciplinary team including a neurologist.	1	c
The timing of the procedures (synchronous or staged) should be determined by local expertise and clinical presentation, targeting the most symptomatic territory first.	lla	e

#### The use of NPD during CAS – class II b/B

#### **Tailored-CAS strategy:**

- the use of **NPD is mandatory** for all CAS procedures
- to fit the NPD (proximal or distal) and stent type (closed- or opencell) to the neurological symptom status, carotid lesion morphology and severity and to carotid and aortic arch anatomy
- minor stroke rate 0.7-1.61%; major stroke rate 0 0.5%

### CAS or CEA prior to cardiac surgery???

### CAS:

### -Less invasive

- does not require general anesthesia (coronary unstable patients!)
- neurological symptom status of the patient is known during whole procedure
- -Lasts up to 20 30 minutes
- no serious bleedings/thrombotic events
- -For tailored-CAS strategy in-hospital and 30-day death/stroke rate 2.2%; no Mis

#### CEA:

- -Coronary unstable/severe MVD patients often postponed from CEA
- neurological symptom status during procedure is unknown (patient under general anesthesia)
- -Prolongs general anesthesia (if procedures are simultaneous)

#### Simultaneous CAS+CABG or CEA+CABG???

- Little evidence is available
- one, small randomized trial by Mićović S et al. (EurJ Cardiothoracic Surg 2014)
- 1:1 randomization into two groups:

group 1 (hybrid CAS+CABG, n=10) vs. group 2 (simultaneous CEA+CABG, n=10)

-All CAS procedures were performed with distal NPD devices and open or closed cell stent implantation, all CAS procedures were successful


- cardiac surgery: only isolated CABG in both groups (one OPCAB)

All complications occurred in CEA+CABG group:
 one death due to multiorgan failure and sepsis
 one contralateral stroke on 4<sup>th</sup> postoperative day

#### Asymptomatic ICA stenosis and coronary bypass grafting

- the **benefit of prophylactic carotid revascularization** in patients with asymptomatic unilateral carotid disease is **uncertain**
- The guidelines: class IIb/C, selected cases...
- On the other hand trials include asymptomatic patients mostly

#### Neurologically asyptomatic ICA stenoses in patients with MVD



Who would leave one of these untreated before cardiac surgery????

### Patient 65 y.o.

- Multivessel coronary artery disease: LAD/Dg 90%, Cx 100%, RCA II segm 90%
- CCS III, neurologically asymptomatic
- History of smoking, hyperlipideamia, gastric ulcer, he had nephrectomy on the right
- and lobectomy of the right lung

#### Scheduled for CABG, not screened for ICA stenosis (although he had indications)

- 1st postoperative day:
- hemiplegia of the left limbs,
- Babinski (+) on the left




Carotid Doppler: a critical RICA stenosis, undiagnosed before CABG 2 weeks later: RICA-CAS



### Patient 62 y.o.

unstable angina and recent transient aphasia

- MVD urgent CABG: LIMA-LAD, SvG-Mg, SvG-RPD
- on the 1<sup>st</sup> postoperative day focal neurological symptoms
- carotid doppler occluddec LICA
- CT large left hemispheric stroke




CT 2<sup>nd</sup> postoperative day

Massive cerebral oedema Patient died on 3<sup>rd</sup> postopoperative day


#### CAS would take 30 minutes...

#### CT 1<sup>st</sup> postoperative day

### CAS



#### **CABG**



LICA – CAS

CABG: LIMA-LAD, RA-Mg (Y-anastomosis)

New treatment strategy in 2016

Thank you for the attention